For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...

The Food and Drug Administration won’t sign off on Sarepta Therapeutics Inc. bringing its controversial gene therapy back to ...

Little Evan, who lives in Maidstone in Kent, was only told he had the debilitating condition on February 8 this year after ...

Sarepta Therapeutics (SRPT) stock is downgraded at Bank of America based on safety concerns related to the company's Elevidys gene therapy for Duchenne. Read more here.

The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in ...

In this week’s edition of InnovationRx, we look at Moderna’s use of quantum computers, a new top drug regulator at the FDA, ...

Roche is pausing shipments of Elevidys in some countries, following partner Sarepta Therapeutics’ move in the U.S., as safety ...

A public workshop that columnist Shalom Lim and his girlfriend, Amanda, organized aimed to foster connection among people ...

Sarepta faces an “arduous and treacherous path” to try to get its Duchenne muscular dystrophy therapy Elevidys back onto the ...

BGENE-DMD is designed to treat Duchenne muscular dystrophy (DMD) via a one-time administration in a single AAV.

In the completed Phase 1/2 EXPLORE44 trial, del-zota demonstrated statistically significant increases in exon skipping, substantial increases in dystrophin production, and a significant reduction in ...